10 free, board-style Hematology questions for the PANRE, each with the correct answer and a complete explanation. No email, no account required.
Hematology is 4% of the PANRE content blueprint. These questions come from the clinician-reviewed FirstPassPA bank. Attempt each one before you reveal the answer.
Question 1HematologyMedium
A 65-year-old man with no prior GI workup is found to have iron deficiency anemia on routine labs (Hgb 10.2 g/dL, MCV 72 fL, ferritin 8 ng/mL). He is asymptomatic and reports no overt bleeding. Which of the following is the most important cause to exclude?
AUndiagnosed celiac disease
BAutoimmune atrophic gastritis
CBleeding peptic ulcer disease
DOccult colorectal malignancy
EInadequate dietary iron intake
Reveal answer & full explanation
Correct answer: D — Occult colorectal malignancy
AUndiagnosed celiac disease
BAutoimmune atrophic gastritis
CBleeding peptic ulcer disease
DOccult colorectal malignancy✓
EInadequate dietary iron intake
Why Occult colorectal malignancy is correct
Iron deficiency in men and postmenopausal women: GI blood loss is assumed until proven otherwise
Colorectal cancer is the most important cause to exclude
Bidirectional endoscopy (colonoscopy plus upper endoscopy, typically in the same session) is indicated because dual pathology occurs
Upper endoscopy evaluates for H. pylori-positive peptic ulcer disease (PUD), gastric cancer, or celiac disease
Why the others are wrong
Bleeding peptic ulcer disease — a genuine source of occult upper GI blood loss and part of the bidirectional endoscopic workup, but a missed colorectal cancer carries far greater consequences, so malignancy remains the priority to exclude in a 65-year-old man
Autoimmune atrophic gastritis — achlorhydria impairs iron absorption, making it a recognized cause of iron deficiency in older adults that often precedes the B12 deficiency of pernicious anemia, but it is diagnosed on gastric biopsies at upper endoscopy and carries none of the consequences of a missed cancer, so colorectal malignancy remains the priority to exclude
Inadequate dietary iron intake — uncommon as the sole cause in an adult man and accepted only after GI blood loss has been excluded
Undiagnosed celiac disease — celiac disease is a recognized cause of iron deficiency from duodenal malabsorption and is part of the evaluation (serology or duodenal biopsies at upper endoscopy), but it is far less likely than colorectal cancer in a 65-year-old man and less consequential if missed, so malignancy remains the priority to exclude
Additional high-yield points
In premenopausal women, menorrhagia is the most common cause of iron deficiency
Management requires both treating the iron deficiency AND identifying the source
Question 2HematologyMedium
A 68-year-old man presents with 4 months of progressive low back pain, fatigue, and a 6 kg unintentional weight loss. Exam shows pallor and tenderness over the lumbar spine. Labs show Hgb 9.1 g/dL, creatinine 2.3 mg/dL, calcium 11.6 mg/dL, total protein 10.2 g/dL with albumin 3.1 g/dL. Serum protein electrophoresis shows a monoclonal IgG kappa spike of 4.2 g/dL. Skeletal survey reveals multiple lytic lesions in the skull and vertebrae. Which of the following bone marrow findings would best establish the diagnosis?
AClonal plasma cells comprising 35% of marrow cellularity
BNests of metastatic carcinoma cells on marrow biopsy
CMarrow infiltration with small mature CD5+ B lymphocytes
DHypercellular marrow with >20% myeloblasts
EReed-Sternberg cells on marrow biopsy
Reveal answer & full explanation
Correct answer: A — Clonal plasma cells comprising 35% of marrow cellularity
AClonal plasma cells comprising 35% of marrow cellularity✓
BNests of metastatic carcinoma cells on marrow biopsy
CMarrow infiltration with small mature CD5+ B lymphocytes
DHypercellular marrow with >20% myeloblasts
EReed-Sternberg cells on marrow biopsy
Why Clonal plasma cells comprising 35% of marrow cellularity is correct
This patient has classic CRAB features of multiple myeloma: hyperCalcemia (11.6 mg/dL), Renal insufficiency (creatinine 2.3 mg/dL), Anemia (Hgb 9.1 g/dL), and lytic Bone lesions, with a large IgG kappa monoclonal protein spike of 4.2 g/dL
Diagnosis per the International Myeloma Working Group requires clonal bone marrow plasma cells ≥10% (or a biopsy-proven plasmacytoma) PLUS at least one myeloma-defining event
Myeloma-defining events include a CRAB feature or a SLiM criterion: clonal marrow plasma cells ≥60%, involved/uninvolved serum free light chain ratio ≥100, or >1 focal lesion on MRI
Marrow showing 35% clonal plasma cells in a patient with CRAB features establishes the diagnosis
Why the others are wrong
Reed-Sternberg cells on marrow biopsy — pathognomonic for Hodgkin lymphoma, which presents with painless lymphadenopathy and B symptoms, not CRAB features or an M-spike
Hypercellular marrow with >20% myeloblasts — defines acute myeloid leukemia, which causes pancytopenia and circulating blasts, not lytic bone lesions or a monoclonal IgG spike
Marrow infiltration with small mature CD5+ B lymphocytes — defines chronic lymphocytic leukemia, which presents with lymphocytosis and lymphadenopathy, not lytic lesions or hypercalcemia
Nests of metastatic carcinoma cells on marrow biopsy — weight loss, back pain, lytic lesions, and hypercalcemia also fit skeletal metastases from a solid tumor, but a carcinoma does not secrete a monoclonal immunoglobulin; an IgG kappa spike of 4.2 g/dL with renal insufficiency and anemia completes the CRAB picture of myeloma, which marrow plasma cells confirm
Question 3HematologyMedium
A 45-year-old woman with systemic lupus erythematosus (SLE) is found to have a platelet count of 22,000/µL. She has no bleeding. A peripheral blood smear shows no schistocytes. PT/INR, aPTT, and fibrinogen are normal, and LDH is normal. Which of the following is the most likely diagnosis?
AAntiphospholipid syndrome (APS)
BImmune thrombocytopenia (ITP)
CDisseminated intravascular coagulation (DIC)
DMacrophage activation syndrome (MAS)
EThrombotic thrombocytopenic purpura (TTP)
Reveal answer & full explanation
Correct answer: B — Immune thrombocytopenia (ITP)
AAntiphospholipid syndrome (APS)
BImmune thrombocytopenia (ITP)✓
CDisseminated intravascular coagulation (DIC)
DMacrophage activation syndrome (MAS)
EThrombotic thrombocytopenic purpura (TTP)
Why Immune thrombocytopenia (ITP) is correct
SLE is a classic cause of secondary immune thrombocytopenia: autoantibodies opsonize platelets for splenic destruction, producing isolated thrombocytopenia
Isolated thrombocytopenia with an otherwise normal smear supports immune-mediated destruction rather than consumption or a microangiopathy; ITP is a diagnosis of exclusion, and anti-platelet antibody testing is not needed to make it
Normal PT/INR, aPTT, and fibrinogen exclude a consumptive coagulopathy; normal LDH and absent schistocytes exclude a microangiopathic hemolytic process
First-line therapy is corticosteroids (with hydroxychloroquine treating the underlying SLE); IVIG gives a rapid pre-procedure rise, and rituximab or splenectomy is reserved for refractory disease
Why the others are wrong
Thrombotic thrombocytopenic purpura (TTP) — would show schistocytes and an elevated LDH from microangiopathic hemolysis, both absent here; a buzzword-matching trap for any low-platelet count in a young woman.
Disseminated intravascular coagulation (DIC) — produces prolonged PT/INR and aPTT, low fibrinogen, and schistocytes from consumption, all of which are normal here; premature-closure trap if a sick lupus patient is assumed to be consuming clotting factors.
Antiphospholipid syndrome (APS) — commonly coexists with SLE and can lower the platelet count, but the diagnosis requires vascular thrombosis or pregnancy morbidity with persistent antiphospholipid antibodies, none of which is described; its thrombocytopenia is usually mild to moderate rather than 22,000/µL, and a lupus anticoagulant typically prolongs the aPTT, which is normal here; a lupus-association trap that skips the defining clinical criteria.
Macrophage activation syndrome (MAS) — a recognized complication of SLE that lowers the platelet count and is easy to reach for in a lupus patient, but its hyperinflammatory picture brings low fibrinogen, a raised LDH, and a very high ferritin, whereas fibrinogen and LDH are normal here; a lupus-complication trap that overlooks the labs.
Question 4HematologyMedium
A 28-year-old male with hemophilia A (factor VIII level 2%) on prophylactic factor VIII develops a severe right knee hemarthrosis after minor trauma. Which of the following is the most appropriate management?
AFresh frozen plasma
BCryoprecipitate
CDesmopressin (DDAVP)
DFactor VIII replacement
ERecombinant factor VIIa
Reveal answer & full explanation
Correct answer: D — Factor VIII replacement
AFresh frozen plasma
BCryoprecipitate
CDesmopressin (DDAVP)
DFactor VIII replacement✓
ERecombinant factor VIIa
Why Factor VIII replacement is correct
Factor VIII concentrate is the cornerstone of treatment: a severe hemarthrosis in hemophilia A is treated immediately with IV FVIII until the bleed resolves. Being on prophylaxis does not change this; a breakthrough bleed needs a treatment dose.
Joint-bleed target is a peak FVIII of about 40-60% for 1-2 days (World Federation of Hemophilia 2020); each 1 IU/kg raises FVIII about 2%, so roughly 20-30 IU/kg.
Adjuncts include RICE and no weight-bearing until pain improves.
Avoid aspirin and nonselective NSAIDs, which impair platelet function; acetaminophen, a selective COX-2 inhibitor, or opioids are acceptable analgesics.
Why the others are wrong
Desmopressin (DDAVP) — FVIII 2% is moderate hemophilia (1-5%), where DDAVP can be considered after a test dose shows an adequate response. But its 3- to 6-fold rise lifts FVIII from 2% to only about 6-12%, far below the 40-60% a severe joint bleed needs, and no test-dose response is documented.
Cryoprecipitate — contains FVIII but is usually not virally inactivated and is imprecisely dosed; not recommended when concentrate is available.
Fresh frozen plasma — carries only about 1 IU/mL of FVIII, so levels above about 30% are hard to reach without volume overload; concentrate is preferred.
Recombinant factor VIIa — tempting because a bleed despite prophylaxis can raise concern for an inhibitor, but bypassing agents are used when an inhibitor, typically a high-responding one, keeps FVIII replacement from working; with no inhibitor documented, FVIII concentrate is the specific replacement that controls this bleed
Additional high-yield points
Severity is graded by baseline FVIII: severe <1%, moderate 1-5%, mild 5-40%.
A joint bleed that fails to respond to adequate FVIII dosing suggests an inhibitor (check a Bethesda assay); high-responding inhibitors are treated with a bypassing agent (recombinant FVIIa or activated prothrombin complex concentrate).
Emicizumab (Hemlibra) is a subcutaneous bispecific antibody for prophylaxis in hemophilia A with or without inhibitors; it does not treat acute bleeds.
Question 5HematologyMedium
A 35-year-old female with presumed antiphospholipid antibody syndrome (APS) based on a single positive anticardiolipin IgG has her second deep vein thrombosis (DVT) while on warfarin (INR 2.1). She has no known triple-positive APS. Which of the following is the most appropriate next step?
ASwitch to apixaban
BPlace an inferior vena cava filter
CAdd clopidogrel to current warfarin
DIncrease warfarin target INR to 4.5-5.0
EConfirm persistent APS antibody status
Reveal answer & full explanation
Correct answer: E — Confirm persistent APS antibody status
ASwitch to apixaban
BPlace an inferior vena cava filter
CAdd clopidogrel to current warfarin
DIncrease warfarin target INR to 4.5-5.0
EConfirm persistent APS antibody status✓
Why Confirm persistent APS antibody status is correct
A single positive anticardiolipin IgG may be transient; antiphospholipid syndrome (APS) diagnosis requires two positive tests at least 12 weeks apart
Before escalating anticoagulation, confirm persistent APS antibody positivity to ensure the diagnosis is truly established
Also evaluate warfarin adherence and drug interactions that may have caused a low INR at the time of the thrombotic event
Why the others are wrong
Increase warfarin target INR to 4.5-5.0 — for confirmed APS with recurrent thrombosis despite therapeutic warfarin, the appropriate INR target increase is to 3.0-4.0 (not 4.5-5.0), or adding low-dose aspirin 81 mg; an INR target of 4.5-5.0 carries excessive bleeding risk
Switch to apixaban — direct oral anticoagulants (DOACs) are not recommended for triple-positive APS (the TRAPS trial showed rivaroxaban was inferior to warfarin); DOACs should be used with extreme caution in APS generally and are not an appropriate escalation after recurrent thrombosis on therapeutic warfarin, where the options are raising the INR target to 3-4, adding low-dose aspirin, or switching to low-molecular-weight heparin
Add clopidogrel to current warfarin — clopidogrel has no established role in APS; when escalation is warranted, the antiplatelet option is low-dose aspirin, and adding clopidogrel to warfarin mainly increases bleeding risk
Place an inferior vena cava filter — a filter is tempting for a clot that recurred on anticoagulation, but IVC filters are reserved mainly for acute VTE when anticoagulation cannot be given; she can still be anticoagulated, a filter does nothing for the underlying hypercoagulable state and raises the long-term risk of recurrent DVT, and recurrence on warfarin calls for confirming the APS diagnosis and then intensifying antithrombotic therapy, not a filter
Question 6HematologyMedium
A 38-year-old woman presents with a 3-day history of fatigue, scattered bruising, and intermittent confusion noted by her family. She has no recent illness, trauma, or new medications. On exam she is febrile and has petechiae over both shins; she is oriented only to person. Labs show hemoglobin 7.8 g/dL, platelets 18,000/uL, LDH 1,420 U/L, haptoglobin undetectable, and creatinine 1.4 mg/dL. PT, aPTT, and fibrinogen are normal, and the direct antiglobulin (Coombs) test is negative. A peripheral smear shows numerous schistocytes. Which of the following is the most likely diagnosis?
AAtypical hemolytic uremic syndrome
BDisseminated intravascular coagulation
CThrombotic thrombocytopenic purpura
DWarm-type autoimmune hemolytic anemia
EPrimary immune thrombocytopenic purpura
Reveal answer & full explanation
Correct answer: C — Thrombotic thrombocytopenic purpura
AAtypical hemolytic uremic syndrome
BDisseminated intravascular coagulation
CThrombotic thrombocytopenic purpura✓
DWarm-type autoimmune hemolytic anemia
EPrimary immune thrombocytopenic purpura
Why Thrombotic thrombocytopenic purpura is correct
The combination of microangiopathic hemolytic anemia (anemia, markedly elevated LDH, undetectable haptoglobin, schistocytes) plus severe thrombocytopenia with NORMAL coagulation studies and a NEGATIVE direct Coombs is the defining picture of a thrombotic microangiopathy, and the prominent neurologic involvement (confusion) with only mild renal injury points to TTP.
TTP results from severe ADAMTS13 deficiency (usually an acquired autoantibody); ultralarge vWF multimers drive platelet-rich microthrombi, causing red-cell shear and organ ischemia.
The classic pentad (hemolytic anemia, thrombocytopenia, neurologic changes, renal dysfunction, fever) is rarely complete — microangiopathic hemolytic anemia plus thrombocytopenia alone warrants treating as TTP until proven otherwise. Emergent plasma exchange plus glucocorticoids should begin before the ADAMTS13 result returns, and platelet transfusion is avoided unless there is life-threatening bleeding.
Why the others are wrong
Disseminated intravascular coagulation — also causes thrombocytopenia and schistocytes, but it prolongs the PT and aPTT, consumes fibrinogen, and raises D-dimer; the normal coagulation panel here excludes it.
Primary immune thrombocytopenic purpura — produces isolated thrombocytopenia without hemolysis, schistocytes, or organ dysfunction; the anemia, elevated LDH, and fragmented red cells are inconsistent with it.
Warm-type autoimmune hemolytic anemia — causes immune (not mechanical) hemolysis with a POSITIVE direct Coombs and spherocytes rather than schistocytes; the negative Coombs and fragmented red cells here argue against it.
Atypical hemolytic uremic syndrome — also a thrombotic microangiopathy with Coombs-negative hemolysis, schistocytes, and normal coagulation studies, but it is complement-mediated and dominated by severe acute kidney injury, usually with a less profound thrombocytopenia; a platelet count of 18,000/uL with prominent confusion and only mild renal injury points to TTP, which severe ADAMTS13 deficiency confirms.
Question 7HematologyMedium
A 72-year-old female develops sudden onset severe headache and confusion while on warfarin for atrial fibrillation (AF) (INR 4.8). Non-contrast CT shows a large right parietal intracerebral hemorrhage with midline shift. Which of the following is the most appropriate immediate management?
ARecombinant activated factor VIIa plus IV tranexamic acid
BIdarucizumab infusion plus IV vitamin K administration
CPlatelet transfusion plus IV desmopressin and cryoprecipitate
D4-factor prothrombin complex concentrate plus IV vitamin K
EFresh frozen plasma transfusion plus IV vitamin K administration
Reveal answer & full explanation
Correct answer: D — 4-factor prothrombin complex concentrate plus IV vitamin K
ARecombinant activated factor VIIa plus IV tranexamic acid
BIdarucizumab infusion plus IV vitamin K administration
CPlatelet transfusion plus IV desmopressin and cryoprecipitate
D4-factor prothrombin complex concentrate plus IV vitamin K✓
EFresh frozen plasma transfusion plus IV vitamin K administration
Why 4-factor prothrombin complex concentrate plus IV vitamin K is correct
4-factor prothrombin complex concentrate (4-PCC) (Kcentra) contains factors II, VII, IX, X, protein C and S — reverses INR within 15-30 minutes.
Given weight-based: 25-50 units/kg depending on INR.
Superior to fresh frozen plasma (FFP): faster, smaller volume, no crossmatch, no thaw time required.
Vitamin K 10 mg IV ensures sustained reversal because PCC lasts only 6-12 hours.
Why the others are wrong
Fresh frozen plasma transfusion plus IV vitamin K administration — second-line if PCC unavailable; requires large volume (15-30 mL/kg), slow infusion, and carries risk of volume overload (right-concept-slower-agent).
Recombinant activated factor VIIa plus IV tranexamic acid — corrects only factor VII, carries thrombotic risk, and is not recommended for warfarin reversal (confused-with wrong agent).
Platelet transfusion plus IV desmopressin and cryoprecipitate — addresses platelet dysfunction and fibrinogen, not warfarin-mediated coagulopathy (confused-with wrong mechanism).
Idarucizumab infusion plus IV vitamin K administration — idarucizumab is the specific reversal agent for dabigatran, which many patients with atrial fibrillation take, but it is an antibody fragment that binds only dabigatran and does nothing for the warfarin-induced deficiency of factors II, VII, IX and X; the INR of 4.8 marks a warfarin coagulopathy that needs immediate factor replacement with 4-PCC (confused-with DOAC reversal)
Additional high-yield points
Direct oral anticoagulant (DOAC) reversal agents: idarucizumab (Praxbind) for dabigatran; 4-PCC for apixaban and rivaroxaban in the US, where andexanet alfa (Andexxa) was withdrawn from the market in December 2025.
INR targets post-reversal: full reversal preferred for life-threatening hemorrhage.
Question 8HematologyMedium
A 30-year-old male with no significant history presents with 3 weeks of fever, night sweats, and 12-lb weight loss. Complete blood count (CBC) shows WBC 11K (normal differential), Hgb 9.8 (normocytic), and platelets 180K. Erythrocyte sedimentation rate (ESR) is 112. LDH is elevated. CT shows mediastinal and bilateral hilar lymphadenopathy. Excisional biopsy of a mediastinal node shows scattered large binucleated cells with prominent eosinophilic nucleoli in a mixed inflammatory background. Which of the following is the most likely diagnosis?
AClassical Hodgkin lymphoma
BInfectious mononucleosis
CTuberculous lymphadenitis
DNon-Hodgkin lymphoma
ESarcoidosis
Reveal answer & full explanation
Correct answer: A — Classical Hodgkin lymphoma
AClassical Hodgkin lymphoma✓
BInfectious mononucleosis
CTuberculous lymphadenitis
DNon-Hodgkin lymphoma
ESarcoidosis
Why Classical Hodgkin lymphoma is correct
Classical Hodgkin lymphoma (cHL) is the most common lymphoma in young adults (bimodal peak: 15-35 and above 55)
The large binucleated cells with prominent eosinophilic (owl-eye) nucleoli on the node biopsy are Reed-Sternberg cells: large CD30+/CD15+ B-cells in an inflammatory background (lymphocytes, eosinophils, plasma cells, neutrophils) — pathognomonic for cHL
B symptoms (fever, night sweats, weight loss), elevated LDH/ESR, and mediastinal/hilar adenopathy round out the classic presentation
Why the others are wrong
Non-Hodgkin lymphoma — lacks Reed-Sternberg cells; shows a clonal lymphoid population on biopsy rather than the mixed inflammatory background (confused-with lymphoma category)
Sarcoidosis — produces bilateral hilar adenopathy but shows non-caseating granulomas, not Reed-Sternberg cells (anchoring on hilar nodes)
Tuberculous lymphadenitis — fever, night sweats, weight loss, high ESR, and mediastinal/hilar adenopathy mimic this presentation, but biopsy would show caseating granulomas with acid-fast bacilli, not large binucleated cells in a mixed inflammatory background (anchoring on constitutional symptoms)
Infectious mononucleosis — EBV causes fever and lymphadenopathy, and reactive immunoblasts in the node can mimic Reed-Sternberg cells, but mono typically presents with pharyngitis, posterior cervical adenopathy, and an atypical lymphocytosis rather than mediastinal and hilar adenopathy with a normal differential (confused-with Reed-Sternberg-like cells)
Treatment: (1) Early favorable (Stage I-IIA): doxorubicin-bleomycin-vinblastine-dacarbazine (ABVD) x2 cycles plus involved-site radiation; (2) Early unfavorable: ABVD x4 cycles plus radiation; (3) Advanced stage (III-IV): brentuximab vedotin-doxorubicin-vinblastine-dacarbazine (BV-AVD) (brentuximab vedotin replacing bleomycin to reduce pulmonary toxicity) or escalated bleomycin-etoposide-doxorubicin-cyclophosphamide-vincristine-procarbazine-prednisone (BEACOPP) (young fit patients)
PET-adapted therapy: interim PET-negative patients can de-escalate
Cure rate: overall 85-90%
Question 9HematologyMedium
A 45-year-old female with lupus is receiving heparin for a deep vein thrombosis (DVT). On day 5 of therapy her platelet count has fallen from 280K to 56K. She now has a new femoral artery thrombosis. Which of the following is the most likely diagnosis?
AHeparin-induced thrombocytopenia type II
BDisseminated intravascular coagulation
CHeparin-induced thrombocytopenia type I
DImmune thrombocytopenia
EThrombotic thrombocytopenic purpura
Reveal answer & full explanation
Correct answer: A — Heparin-induced thrombocytopenia type II
AHeparin-induced thrombocytopenia type II✓
BDisseminated intravascular coagulation
CHeparin-induced thrombocytopenia type I
DImmune thrombocytopenia
EThrombotic thrombocytopenic purpura
Why Heparin-induced thrombocytopenia type II is correct
HIT type II occurs when heparin-platelet factor 4 (PF4) immune complexes activate platelets, causing paradoxical venous AND arterial thrombosis
Classic features present here: platelet drop from 280K to 56K by day 5 of heparin (the 5-10 day window) and a new femoral artery thrombosis; a greater-than-50% fall with this timing and new thrombosis yields a high-probability 4T score
Confirm with a PF4-heparin ELISA, then the serotonin release assay (gold standard)
Management: stop ALL heparin immediately (including LMWH, which cross-reacts) and start a non-heparin anticoagulant such as argatroban, fondaparinux, or a DOAC
Warfarin is contraindicated during active HIT (depletes protein C, causing venous limb gangrene/skin necrosis) until platelets recover above 150K
Why the others are wrong
Disseminated intravascular coagulation — produces consumptive coagulopathy with prolonged PT/PTT, low fibrinogen, and bleeding, not an isolated heparin-timed platelet fall with new arterial thrombosis (confused-with consumptive thrombocytopenia)
Immune thrombocytopenia — causes isolated thrombocytopenia with bleeding risk, not new thrombosis timed to heparin exposure (anchoring on low platelets)
Thrombotic thrombocytopenic purpura — presents with microangiopathic hemolytic anemia and neurologic symptoms, not heparin-triggered arterial thrombosis (confused-with thrombotic microangiopathy)
Heparin-induced thrombocytopenia type I — the heparin exposure makes it tempting, but type I is a benign nonimmune fall that occurs within the first 2 days, is mild (platelets rarely below 100K), resolves despite continued heparin, and causes no thrombosis; a greater-than-50% fall on day 5 with a new arterial thrombosis is immune-mediated type II (confused-with the benign early type)
Question 10HematologyMedium
A 68-year-old male with a second unprovoked DVT (18 months after completing 6 months of rivaroxaban) has no identifiable precipitant. Which of the following is the most appropriate anticoagulation duration?
ASix months of rivaroxaban
BIndefinite anticoagulation
CIndefinite aspirin 81 mg
DTwelve months of rivaroxaban
EThree months of rivaroxaban
Reveal answer & full explanation
Correct answer: B — Indefinite anticoagulation
ASix months of rivaroxaban
BIndefinite anticoagulation✓
CIndefinite aspirin 81 mg
DTwelve months of rivaroxaban
EThree months of rivaroxaban
Why Indefinite anticoagulation is correct
Recurrent unprovoked venous thromboembolism (VTE): indefinite anticoagulation is recommended per American College of Chest Physicians (ACCP) and American Society of Hematology (ASH) guidelines
Recurrence risk off anticoagulation is high: about 10% in the first year and 30% at 5 years after a first unprovoked VTE, and an estimated 1.5 times higher after a second (about 15% in the first year and 45% at 5 years)
This patient already recurred after a finite course, confirming the need for extended therapy
Why the others are wrong
Three months of rivaroxaban — insufficient duration given the high recurrence risk after a second unprovoked VTE (undertreatment)
Indefinite aspirin 81 mg — aspirin is inferior to anticoagulants for VTE secondary prevention (right-concept-wrong-drug)
Six months of rivaroxaban — also insufficient; this patient already completed 6 months after the first event and still recurred (anchoring on prior course)
Twelve months of rivaroxaban — a longer fixed course feels like a reasonable compromise with bleeding risk, but recurrence risk after a second unprovoked VTE persists and returns once anticoagulation stops, so guidelines recommend extended therapy with no scheduled stop date and periodic reassessment rather than an arbitrary 12-month endpoint (arbitrary finite extension)
Additional high-yield points
Extended-duration low-dose options: apixaban 2.5 mg BID (AMPLIFY-EXT: 80% relative risk reduction vs placebo) or rivaroxaban 10 mg daily (EINSTEIN-CHOICE: superior to aspirin)
Annual risk-benefit reassessment: bleeding risk increases with age and comorbidities
Thrombophilia testing: perform after completing anticoagulation (results are unreliable while on anticoagulants)
That's 10 of 7,700+. Get the rest.
Unlock the full FirstPassPA bank: 7,700+ board-style questions across every organ system, flashcards, and an AI tutor that explains every answer. Your 7-day free trial includes everything, and there's no credit card required.
Are these Hematology PANRE practice questions free?
Yes. Each question shows the full vignette, the correct answer, and a complete explanation, with no email or account required. A free 7-day trial unlocks the full 7,700+ question bank, flashcards, and an AI tutor.
How much of the PANRE is Hematology?
Hematology makes up 4% of the PANRE content blueprint. FirstPassPA's timed PANRE exams are dealt to the same weights, so a practice exam carries the same share of Hematology questions.
How should I use these questions?
Attempt each vignette before you reveal the answer, then read the full explanation even when you got it right: the reasons each wrong choice is wrong are where most of the learning is. When you are ready for more, practice Hematology questions in the app, or take a full timed PANRE practice exam dealt to the blueprint weights.
Educational use only. These questions are a study aid for PA students and are not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.